Cargando…

Busulfan‐containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study

BACKGROUND: Allogeneic stem cell transplantation (allo‐HSCT) is the ultimate cure for acute lymphoblastic leukemia (ALL). AIM: This study was performed to compare the outcomes of ALL patients receiving busulfan (Bu) with cyclophosphamide (Cy)‐based or total body irradiation (TBI)‐based regimen in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yu‐Hung, Tien, Feng‐Ming, Tsai, Cheng‐Hong, Huang, Huai‐Hsuan, Liu, Jia‐Hau, Liao, Xiu‐Wen, Tang, Jih‐Luh, Yao, Ming, Ko, Bor‐Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955073/ https://www.ncbi.nlm.nih.gov/pubmed/34196132 http://dx.doi.org/10.1002/cnr2.1488

Ejemplares similares

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
por: Nguyen, Ai-Hoc, et al.
Publicado: (2022)

Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
por: Lemoli, Roberto M., et al.
Publicado: (2011)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
por: Chen, S., et al.
Publicado: (2022)

Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation
por: Chiang, Yun, et al.
Publicado: (2016)

Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia
por: Shi, Yuan-Yuan, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
por: Chen, Rong-Long, et al.
Publicado: (2021)

Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan‐Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation
por: El‐Serafi, Ibrahim, et al.
Publicado: (2019)

GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
por: Ansari, Marc, et al.
Publicado: (2017)

Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan
por: Chen, Chien-Yuan, et al.
Publicado: (2018)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT)
por: Ramzi, Mani, et al.
Publicado: (2020)

Antitumor Activity and Neutrophil‐selective Hematopoietic Toxicity of Busulfan Analogs in Mice
por: Kato, Taketoshi, et al.
Publicado: (1988)

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning
por: Germeraad, R. S., et al.
Publicado: (2022)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Successful hematopoietic stem cell transplantation with reduced dose of busulfan for Omenn syndrome
por: Matsukawa, Yukihiro, et al.
Publicado: (2022)

Role of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia
por: Lussana, Federico, et al.
Publicado: (2014)

Cytomegalovirus pneumonia in a patient with T-lymphoblastic leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: A case report
por: Li, Qiuyu, et al.
Publicado: (2019)

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2019)

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
por: Shin, Ho Cheol, et al.
Publicado: (2012)

Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients
por: Salvaris, Ross, et al.
Publicado: (2022)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
por: Mardani, Masoud, et al.
Publicado: (2020)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Murthy, Guru Subramanian Guru, et al.
Publicado: (2023)

Prophylaxis and treatment of acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
por: Chen, Runzhe, et al.
Publicado: (2015)

An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia
por: Chang, Kiju, et al.
Publicado: (2017)

Genetic Profiling in Children With Acute Lymphoblastic Leukemia Referred for Allogeneic Hematopoietic Stem Cell Transplantation
por: Kwiecinska, Kinga, et al.
Publicado: (2022)

Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa
por: Wagh, Himanshu, et al.
Publicado: (2022)

Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia
por: Liu, Jia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_14mjqha4ubav01e1qonr4s57d0